MBX Biosciences, Inc. (MBX) vs Recursion Pharmaceuticals, Inc. (RXRX)

MBX Biosciences, Inc. and Recursion Pharmaceuticals, Inc. are both Biotechnology companies. MBX Biosciences, Inc. and Recursion Pharmaceuticals, Inc. are of similar size ($2.3B and $2.2B). MBX Biosciences, Inc. has the higher net margin (0.00% vs −697.1%) and the higher return on invested capital (0.00% vs −88.5%). Across the 13 metrics below, MBX Biosciences, Inc. leads on 11 and Recursion Pharmaceuticals, Inc. on 2.

Valuation

Metric MBX RXRX Biotechnology median
P/E n/m n/m 10.26
P/S n/m 27.93 9.18
P/B 5.66 2.10 2.05
Price to free cash flow n/m n/m 24.81
EV/EBITDA n/m n/m 0.65
EV/Sales n/m 19.78 8.98
Earnings yield (4.96%) (25.62%) (34.89%)
Free cash flow yield (3.68%) (16.50%) (24.52%)

Profitability

Metric MBX RXRX Biotechnology median
Gross margin — 29.21% 65.16%
Operating margin 0.00% (725.44%) 0.00%
Net margin 0.00% (697.13%) 0.00%
Free cash flow margin 0.00% (460.89%) 0.00%
Return on equity (33.17%) (48.72%) (50.12%)
Return on assets (31.25%) (36.29%) (45.60%)
Return on invested capital 0.00% (88.54%) 0.00%

Growth

Metric MBX RXRX Biotechnology median
Revenue growth (TTM) — 56.18% 6.26%
EPS growth (last fiscal year) 59.11% 14.79% 29.88%
Revenue growth, 5-year CAGR — 79.91% 9.75%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric MBX RXRX Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 18.08 5.01 4.89
Net debt to EBITDA 3.82 1.31 1.01

Dividend

Metric MBX RXRX Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric MBX RXRX Biotechnology median
Market cap 2.33b 2.18b 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack